Foundational Science and Mechanisms of Disease

426 questions

Question 241Question →

A 38-year-old man is evaluated in the hospital for a progressive rash and severe diarrhea. Five weeks ago, he underwent a matched-unrelated donor allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia. His conditioning regimen included total body irradiation and high-dose cyclophosphamide. Over the past four days, he has developed a diffuse, pruritic maculopapular rash that prominently involves his palms, soles, and posterior trunk. He also reports crampy abdominal pain and large-volume, watery diarrhea, with nursing staff measuring approximately 1.5 liters of stool output yesterday. Vital signs are temperature 38.1°C (100.6°F), blood pressure 110/70 mmHg, heart rate 98/min, and respiratory rate 16/min. Physical examination confirms the described rash and reveals mild scleral icterus. Laboratory studies show:

Total bilirubin: 4.8 mg/dL
Direct bilirubin: 3.5 mg/dL
Alkaline phosphatase: 420 U/L
Aspartate aminotransferase (AST): 85 U/L
Alanine aminotransferase (ALT): 92 U/L

Which of the following best describes the primary immunopathogenesis of this patient's current clinical syndrome?

Show answer & explanation

Answer: Activation of mature donor T lymphocytes by recipient histocompatibility antigens

Answer

Activation of mature donor T lymphocytes by recipient histocompatibility antigens
The correct answer accurately describes the pathophysiology of acute graft-versus-host disease (aGVHD). This patient's presentation 5 weeks after an allogeneic hematopoietic stem cell transplant with a maculopapular rash (classically involving palms and soles), large-volume watery diarrhea, and cholestatic jaundice represents the classic clinical triad of aGVHD. The immunopathogenesis of aGVHD fundamentally requires three conditions: (1) the graft must contain immunocompetent cells (mature donor T lymphocytes), (2) the recipient must express antigens (major or minor histocompatibility antigens) that are not present in the donor, and (3) the recipient must be immunologically compromised (due to the conditioning regimen) and thus unable to destroy the grafted cells. The mature donor T cells recognize host tissues as foreign, proliferate, and mediate widespread tissue damage, primarily targeting the skin, liver, and gastrointestinal epithelium.

Step-by-Step Solution

1
Analyze the patient's history and timeline of symptom onset.
The patient is 5 weeks post-allogeneic hematopoietic stem cell transplantation (HSCT).
The timing is critical for differentiating early post-transplant complications, placing him in the typical window for acute rather than chronic conditions.
2
Identify the clinical syndrome based on the triad of presenting signs.
The combination of a maculopapular rash (including palms and soles), profuse watery diarrhea, and cholestatic liver injury (elevated bilirubin and alkaline phosphatase) is the classic triad of acute graft-versus-host disease (aGVHD).
Recognizing this specific pattern of target organ involvement (skin, gastrointestinal tract, and liver) is essential for diagnosing aGVHD in post-HSCT patients.
3
Determine the precise immunologic mechanism underlying this diagnosis.
In aGVHD, the transplanted (donor) immune system recognizes the recipient (host) tissues as foreign and mounts an immune attack.
Because the host's native immune system was ablated during the conditioning regimen, the host cannot attack the graft. Instead, immunocompetent donor T cells present in the stem cell graft become activated against host major and minor histocompatibility antigens.

Key Concept

The immunopathogenesis of acute graft-versus-host disease (aGVHD) involves donor-derived immunocompetent T cells recognizing and attacking recipient alloantigens, typically manifesting with skin, liver, and gastrointestinal involvement.
Question 242Question →

Correlate the following specific cellular and molecular biopsy findings with the targeted pharmacologic agent most appropriate for exploiting that underlying neoplastic mechanism.

Click a left item, then click its matching right item

Items

Biopsy of a breast mass in a premenopausal patient reveals invasive carcinoma with marked ERBB2 gene amplification.
Bone marrow aspirate from a patient presenting with marked leukocytosis shows myeloid cells harboring the t(9;22)(q34;q11) translocation.
Tissue analysis of metastatic non-small cell lung cancer in a lifelong non-smoker demonstrates an EML4-ALK inversion.
Molecular profiling of recurrent high-grade serous ovarian carcinoma identifies a deleterious germline BRCA1 mutation.

Matches

Show answer & explanation

Answer

The correct matches pair the specific foundational molecular derangement identified in the biopsy with its corresponding targeted pharmacologic inhibitor.
Each correct pair accurately links a fundamental molecular derangement within a neoplastic cell to the pharmacologic agent specifically designed to inhibit or exploit that altered pathway.

Step-by-Step Solution

1
Analyze the molecular and genetic findings described for each neoplastic tissue sample.
Identified the specific pathogenic drivers: HER2 receptor amplification, BCR-ABL fusion kinase, ALK fusion kinase, and BRCA1-mediated homologous recombination deficiency.
Understanding the foundational mechanism driving the neoplastic process is essential to successfully selecting modern targeted therapies.
2
Correlate each identified molecular driver with its specific pharmacologic inhibitor.
Matched the molecular targets to trastuzumab, imatinib, crizotinib, and olaparib, respectively.
Targeted biologic therapies exploit highly specific cellular vulnerabilities, which differ significantly across varying cancer types.

Key Concept

Targeted oncologic therapies exploit specific molecular vulnerabilities characteristic of distinct neoplastic processes, such as oncogene addiction (e.g., HER2, BCR-ABL, ALK) or synthetic lethality (e.g., PARP inhibition in BRCA-mutated cells).
Question 243Question →

An obstetrician is asked to evaluate a patient in the emergency department. The patient, pregnant with twins at 1010 weeks gestation, has been experiencing intractable vomiting, leading to severe dehydration and a weight loss of 4 kg4\text{ kg} (8.8 lbs8.8\text{ lbs}) over the last two weeks. During the evaluation, the physician notes a resting heart rate of 115/min115/\text{min} and a fine resting tremor. The patient mentions she feels constantly hot despite the room being air-conditioned. Examination of the neck reveals no thyromegaly or cervical lymphadenopathy, and eye examination is unremarkable.

Initial laboratory investigations show a human chorionic gonadotropin (hCG) level of 245,000 mIU/mL245,000\text{ mIU/mL}, a suppressed thyroid-stimulating hormone (TSH) level of 0.05 \muU/mL0.05\text{ \mu U/mL}, and an elevated free thyroxine (free T4) level of 2.5 ng/dL2.5\text{ ng/dL}.

Which of the following best explains the cellular mechanism underlying this patient's abnormal thyroid laboratory profile?

Show answer & explanation

Answer: Activation of the G-protein-coupled thyrotropin receptor by a structurally homologous placental glycoprotein

Answer

Activation of the G-protein-coupled thyrotropin receptor by a structurally homologous placental glycoprotein
The correct answer accurately describes the mechanism of gestational transient thyrotoxicosis. Human chorionic gonadotropin (hCG) is a glycoprotein that shares an identical alpha subunit with thyroid-stimulating hormone (TSH), luteinizing hormone (LH), and follicle-stimulating hormone (FSH). In conditions where hCG levels are exceptionally high, such as hyperemesis gravidarum, multiple gestations, or molar pregnancies, the beta subunit of hCG exhibits enough structural homology to directly bind and stimulate the G-protein-coupled TSH receptor on thyroid follicular cells. This stimulation leads to increased production of thyroid hormones (elevated free T4), which exerts negative feedback on the pituitary, resulting in a suppressed TSH level.

Step-by-Step Solution

1
Analyze the clinical presentation and laboratory findings.
The patient has clinical thyrotoxicosis (tachycardia, tremor, heat intolerance) with laboratory confirmation (suppressed TSH, elevated free T4) in the setting of hyperemesis gravidarum and twin gestation.
Establishing the functional thyroid status and correlating it with the specific pregnancy complications is required to identify the etiology.
2
Identify the hormonal abnormalities associated with the patient's specific pregnancy state.
Twin gestation and hyperemesis gravidarum are both characterized by exceptionally high levels of human chorionic gonadotropin (hCG), which is confirmed by the lab value of 245,000 mIU/mL245,000\text{ mIU/mL}.
Connecting the obstetric findings to the endocrine profile narrows down the pathophysiological mechanism.
3
Determine the biochemical relationship between hCG and thyroid function.
hCG shares an identical alpha subunit with TSH. High levels of hCG cross-react with the TSH receptor, stimulating the thyroid gland to produce excess T4 and subsequently suppressing endogenous TSH.
This structural homology perfectly explains the transient thyrotoxicosis without requiring an underlying autoimmune or destructive thyroid pathology.

Key Concept

Gestational transient thyrotoxicosis occurs because hCG shares an identical alpha subunit with TSH; at very high concentrations (e.g., hyperemesis gravidarum, multiple gestation), hCG directly stimulates the TSH receptor.
Question 244Question →

A 29-year-old man is evaluated in the hypertension clinic for persistently elevated blood pressure. He was diagnosed with hypertension at age 21 and is currently taking maximally tolerated doses of amlodipine, lisinopril, and chlorthalidone with poor control. He reports occasional muscle cramps but no headaches, palpitations, or diaphoresis. Family history is notable for his father, who developed severe hypertension in his twenties and died of a hemorrhagic stroke at age 42.

Blood pressure is 168/104 mm Hg and heart rate is 76/min. BMI is 24 kg/m². Physical examination reveals no abdominal bruits, striae, or abnormal fat distribution.

Laboratory results are as follows:

Laboratory StudyResultReference Range
Sodium145 mEq/L136-145 mEq/L
Potassium2.9 mEq/L3.5-5.0 mEq/L
Chloride104 mEq/L98-106 mEq/L
Bicarbonate31 mEq/L22-28 mEq/L
Creatinine0.9 mg/dL0.7-1.3 mg/dL
Plasma renin activity0.1 ng/mL/hr0.6-4.3 ng/mL/hr
Serum aldosterone32 ng/dL3-16 ng/dL

An unenhanced CT scan of the abdomen demonstrates bilateral adrenal enlargement without discrete masses. Following a 4-week therapeutic trial with low-dose oral dexamethasone, the patient's blood pressure decreases to 126/82 mm Hg and serum potassium rises to 4.3 mEq/L.

Which of the following is the most likely molecular mechanism underlying this patient's condition?

Show answer & explanation

Answer: Formation of a chimeric gene combining an ACTH-responsive promoter with the aldosterone synthase coding region

Answer

Formation of a chimeric gene combining an ACTH-responsive promoter with the aldosterone synthase coding region
The clinical presentation of primary hyperaldosteronism (hypertension, hypokalemia, elevated aldosterone, suppressed renin) that resolves with exogenous glucocorticoids (dexamethasone) is diagnostic of Glucocorticoid-Remediable Aldosteronism (Familial Hyperaldosteronism Type I). This autosomal dominant condition results from an unequal crossing-over event during meiosis between two closely linked genes on chromosome 8: CYP11B1 (which encodes 11-beta-hydroxylase, normally regulated by ACTH) and CYP11B2 (which encodes aldosterone synthase, normally regulated by angiotensin II). The resulting chimeric gene places the coding sequence for aldosterone synthase under the control of the ACTH-responsive CYP11B1 promoter. Consequently, aldosterone is secreted in an ACTH-dependent manner rather than in response to renin/angiotensin II. Dexamethasone suppresses pituitary ACTH secretion, thereby silencing the chimeric gene and normalizing aldosterone production.

Step-by-Step Solution

1
Analyze the patient's clinical and laboratory presentation.
The patient has severe, early-onset, resistant hypertension with hypokalemia, metabolic alkalosis, suppressed plasma renin activity, and elevated serum aldosterone.
These findings establish a clear diagnosis of primary hyperaldosteronism (renin-independent aldosterone hypersecretion).
2
Evaluate the imaging and therapeutic trial results.
CT shows bilateral adrenal hyperplasia. Low-dose dexamethasone completely normalizes blood pressure and potassium levels.
While bilateral idiopathic hyperplasia is a common cause of primary hyperaldosteronism, the complete resolution of the biochemical and clinical abnormalities with exogenous glucocorticoids (dexamethasone) is pathognomonic for Glucocorticoid-Remediable Aldosteronism (GRA).
3
Identify the molecular mechanism of GRA.
GRA is caused by an unequal meiotic crossing-over event that fuses the ACTH-responsive promoter of CYP11B1 to the coding sequence of CYP11B2.
This genetic alteration places aldosterone synthesis under the regulatory control of ACTH rather than angiotensin II. Exogenous dexamethasone suppresses pituitary ACTH, thereby removing the stimulus for the chimeric gene and halting excess aldosterone production.

Key Concept

Glucocorticoid-Remediable Aldosteronism (GRA) is a familial cause of primary hyperaldosteronism resulting from a chimeric gene fusion that places aldosterone synthase under ACTH regulation.
Question 245Question →

A 64-year-old man presents to the emergency department with a 4-day history of severe, crampy abdominal pain and 8 to 10 watery, non-bloody bowel movements daily. He was diagnosed with metastatic non-small cell lung cancer 3 months ago. Genomic testing of his tumor revealed high expression of a ligand that binds to an inhibitory T-cell receptor. Based on these findings, he recently began targeted monoclonal antibody therapy, receiving his last infusion 10 days ago. His temperature is 37.9°C (100.2°F), blood pressure is 102/65 mm Hg, and pulse is 112/min. Physical examination reveals dry mucous membranes and diffuse abdominal tenderness without rigidity, rebound, or guarding. Laboratory studies show a serum creatinine of 1.4 mg/dL (baseline 0.9 mg/dL) and a white blood cell count of 11,500/mm³. Rapid stool testing for Clostridioides difficile toxin is negative. Which of the following is the most appropriate next step in management?

Show answer & explanation

Answer: Initiate intravenous methylprednisolone and permanently discontinue the targeted monoclonal antibody therapy

Answer

Initiate intravenous methylprednisolone and permanently discontinue the targeted monoclonal antibody therapy
The correct intervention involves halting the immunotherapy permanently and administering systemic steroids. The patient's history of targeted therapy for a tumor expressing a ligand for an inhibitory T-cell receptor indicates he is taking a PD-1 or PD-L1 inhibitor. These immune checkpoint inhibitors restore T-cell-mediated anti-tumor immunity but frequently disrupt self-tolerance, causing autoimmune toxicities known as immune-related adverse events (irAEs). This patient is presenting with Grade 3 immune-mediated colitis (defined as an increase of ≥7 stools per day over baseline, or symptoms interfering with activities of daily living). Standard management for Grade 3 or 4 irAEs requires immediate hospitalization, initiation of high-dose intravenous corticosteroids (such as methylprednisolone), and permanent discontinuation of the checkpoint inhibitor.

Step-by-Step Solution

1
Identify the mechanism of the patient's antineoplastic therapy.
The tumor expresses a ligand binding to an inhibitory T-cell receptor (PD-L1), indicating the patient is receiving an immune checkpoint inhibitor (e.g., pembrolizumab or nivolumab).
Identifying the drug class is necessary to anticipate its specific, mechanism-based adverse effect profile.
2
Evaluate the clinical severity of the patient's gastrointestinal presentation.
The patient has 8 to 10 watery stools daily along with dehydration and acute kidney injury, which classifies as Grade 3 (severe) colitis.
Toxicity grading directly dictates the algorithmic management of immune-related adverse events.
3
Determine the appropriate intervention for severe immune-mediated colitis.
Administration of systemic high-dose corticosteroids and the permanent cessation of the immunotherapy.
Grade 3 and 4 immune-mediated toxicities require immediate suppression of the overactive immune response to prevent life-threatening bowel perforation or toxic megacolon.

Key Concept

Severe (Grade 3 or 4) immune-mediated colitis secondary to immune checkpoint inhibitors (e.g., PD-1/PD-L1 antagonists) requires prompt administration of systemic high-dose corticosteroids and permanent discontinuation of the offending immunotherapy agent.
Estimated Time:1m 15s
Question 246Question →

A 38-year-old patient is admitted to the diagnostic evaluation unit for recurrent episodes of diaphoresis, palpitations, and confusion that resolve rapidly with carbohydrate intake. A supervised 72-hour fasting test is initiated, and comprehensive laboratory studies are drawn when the patient develops symptomatic hypoglycemia (capillary blood glucose 42 mg/dL). Match each distinct laboratory profile below with its most likely underlying pathophysiologic mechanism.

Click a left item, then click its matching right item

Items

Serum insulin elevated, C-peptide elevated, proinsulin elevated, negative oral secretagogue screen
Serum insulin elevated, C-peptide suppressed, proinsulin suppressed, negative oral secretagogue screen
Serum insulin elevated, C-peptide elevated, proinsulin normal, positive oral secretagogue screen
Serum insulin suppressed, C-peptide suppressed, elevated IGF-II, low beta-hydroxybutyrate

Matches

Show answer & explanation

Answer

Profile L1 matches autonomous exocytosis (insulinoma). Profile L2 matches direct hormone administration (exogenous insulin). Profile L3 matches K-ATP channel closure (sulfonylurea). Profile L4 matches paraneoplastic receptor activation (non-islet cell tumor hypoglycemia).
Each laboratory profile uniquely maps to a pathophysiologic mechanism of hypoglycemia. Elevated insulin with high C-peptide and a negative drug screen points to an insulinoma (autonomous neuroendocrine secretion). High insulin with low C-peptide indicates exogenous insulin injection, as commercial preparations lack the cleavage byproduct. High insulin and C-peptide with a positive drug screen confirms sulfonylurea use, which pharmacologically closes K-ATP channels. Low insulin and C-peptide with high IGF-II indicates a paraneoplastic syndrome where the tumor secretes a peptide that activates peripheral insulin receptors.

Step-by-Step Solution

1
Analyze the relationship between serum insulin and C-peptide to differentiate endogenous from exogenous hyperinsulinemia.
Elevated insulin with suppressed C-peptide identifies exogenous administration, while concurrent elevation of both points to an endogenous source.
Endogenous insulin is secreted in a 1:1 equimolar ratio with C-peptide, whereas pharmaceutical insulin preparations do not contain C-peptide.
2
Evaluate the oral secretagogue screen in profiles with endogenous hyperinsulinemia.
A positive screen identifies pharmacologic stimulation of beta cells, whereas a negative screen points to autonomous tumor secretion.
Sulfonylureas and meglitinides artificially stimulate endogenous insulin release by closing K-ATP channels, mimicking an insulinoma.
3
Identify non-insulin-mediated mechanisms in profiles with suppressed insulin and C-peptide.
Hypoglycemia with suppressed beta-cell function and elevated IGF-II indicates a paraneoplastic syndrome.
Tumor-secreted IGF-II binds to insulin receptors, driving glucose into tissues while appropriately suppressing endogenous pancreatic beta-cell activity via negative feedback.

Key Concept

Pathophysiologic mechanisms and diagnostic laboratory profiles of fasting hypoglycemia
Question 247Question →

A 42-year-old man presents to the hospital with a 2-day history of low-grade fever, malaise, decreased urine output, and allograft tenderness. He underwent a deceased-donor kidney transplantation 2 months ago. His current medications include tacrolimus, mycophenolate mofetil, and prednisone. His serum creatinine has abruptly increased from a baseline of 1.3 mg/dL1.3 \text{ mg/dL} to 2.9 mg/dL2.9 \text{ mg/dL}. Initial laboratory studies show a subtherapeutic serum tacrolimus trough level. Urinalysis reveals mild proteinuria but is negative for infection.

Arrange the following steps in the most appropriate sequence for the continued evaluation and management of this patient's allograft dysfunction, from initial structural evaluation to the escalation of therapy for refractory immunologic disease.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct sequence is to first perform a renal allograft Doppler ultrasound, followed by a percutaneous renal allograft biopsy, then administer pulse-dose intravenous methylprednisolone, and finally administer intravenous anti-thymocyte globulin if the condition is refractory.
The proper sequence begins with excluding non-immunologic causes of acute kidney injury. A Doppler ultrasound is noninvasive and effectively rules out vascular thrombosis or urinary obstruction. Once anatomical causes are excluded, a percutaneous renal biopsy is performed to establish a definitive histologic diagnosis. With the diagnosis confirmed, first-line therapy with pulse-dose intravenous corticosteroids is initiated to suppress T-lymphocyte activity. If the patient's allograft function does not improve, therapy is escalated to include T-cell depleting agents like anti-thymocyte globulin.

Step-by-Step Solution

1
Evaluate for structural or vascular abnormalities
Renal allograft Doppler ultrasound is performed.
Anatomic causes of acute kidney injury must be excluded noninvasively before an invasive biopsy is attempted.
2
Establish a definitive tissue diagnosis
A percutaneous renal allograft biopsy is obtained.
Histopathologic evaluation is required to confirm acute cellular rejection and guide targeted immunosuppressive therapy.
3
Initiate first-line treatment for acute cellular rejection
Pulse-dose intravenous methylprednisolone is administered.
High-dose corticosteroids are the standard initial therapy for acute cellular rejection.
4
Escalate treatment for refractory rejection
Intravenous anti-thymocyte globulin is administered.
Lymphocyte-depleting agents are reserved for patients who do not respond adequately to initial corticosteroid therapy.

Key Concept

The diagnostic workup for acute renal allograft dysfunction follows a stepwise approach: ruling out structural/vascular etiologies, confirming immunopathologic diagnosis with biopsy, initiating targeted therapy with corticosteroids, and escalating to depleting antibodies if refractory.
Question 248Question →

A 6666-year-old man presents to the internal medicine clinic for a routine health maintenance visit. He reports a six-month history of mild urinary urgency, frequency, and nocturia, but denies any weight loss, bone pain, hematuria, or dysuria. He has no significant past medical history. Examination reveals a slightly enlarged, firm, and asymmetric prostate. As part of a comprehensive evaluation for a potential neoplastic process of the prostate, the physician considers the appropriate diagnostic and therapeutic algorithm.

Arrange the following diagnostic and management steps in the most appropriate chronological order according to current oncologic guidelines.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct sequence begins with initial screening (PSA and DRE), followed by imaging (multiparametric MRI) to identify biopsy targets, tissue sampling (core needle biopsy), histopathologic evaluation (Gleason scoring), and finally, determining the definitive management plan.
The standard of care for evaluating a potential prostate neoplasm begins with establishing clinical suspicion via PSA and DRE. Because systematic random biopsies have a high false-negative rate, modern oncologic guidelines stipulate obtaining a multiparametric MRI next to identify specific high-risk targets. Once a target is identified, an ultrasound-guided core needle biopsy (often fusing the MRI images) is performed. The resulting tissue is pathologically analyzed to assign a Gleason score. Only after the histologic grade and stage are fully characterized can a definitive management plan, such as active surveillance or surgery, be safely initiated.

Step-by-Step Solution

1
Measure serum prostate-specific antigen (PSA) and perform a digital rectal examination (DRE).
Establishes initial clinical suspicion and risk level for a prostatic neoplasm.
Non-invasive baseline screening must be performed to justify further advanced imaging or invasive procedures.
2
Obtain a multiparametric MRI (mpMRI) of the prostate.
Locates discrete, suspicious intraprostatic lesions and assigns a PI-RADS score.
Performing an MRI before a biopsy increases the detection of clinically significant cancers and allows for precise targeting.
3
Perform a targeted, ultrasound-guided core needle biopsy.
Procures direct tissue samples from the suspected neoplastic lesions.
Histologic material is required to confirm the presence of malignant cells.
4
Analyze the histopathologic specimens for a Gleason score.
Determines the histologic grade and biologic aggressiveness of the cancer.
Tumor grade is a critical prognostic factor that dictates appropriate treatment pathways.
5
Initiate definitive management.
Provides appropriate oncologic care (e.g., active surveillance or surgery).
Therapy must be tailored to the confirmed diagnosis and risk stratification established in the previous steps.

Key Concept

Sequential diagnostic and staging algorithm for prostate cancer, prioritizing non-invasive imaging prior to biopsy.
Question 249Question →

A 62-year-old man comes to the clinic for a routine follow-up. He has a 10-year history of type 2 diabetes mellitus and a history of heart failure with preserved ejection fraction (ejection fraction of 55%55\%). His current medications include metformin, lisinopril, and amlodipine. He feels well and reports no shortness of breath, orthopnea, or lower extremity edema. His blood pressure is 128/78 mm Hg128/78 \text{ mm Hg}, and his pulse is 72/min72/\text{min}. Physical examination reveals clear lungs bilaterally and no jugular venous distention. Laboratory evaluation shows a hemoglobin A1c of 8.6%8.6\%. The physician considers adding pioglitazone to the patient's regimen to improve glycemic control but decides against it due to the patient's cardiac history. Which of the following best describes the cellular mechanism by which the avoided medication promotes fluid retention?

Show answer & explanation

Answer: Upregulation of epithelial sodium channel transcription in the renal collecting tubules

Answer

The avoided medication promotes fluid retention via the upregulation of epithelial sodium channel transcription in the renal collecting tubules.
Pioglitazone is a thiazolidinedione (TZD) that exerts its pharmacological effects by binding to and activating the peroxisome proliferator-activated receptor-gamma (PPAR-\gamma), an intracellular nuclear transcription factor. While its primary therapeutic effect is improving insulin sensitivity in adipose tissue and skeletal muscle, PPAR-\gamma receptors are also abundantly expressed in the principal cells of the renal collecting tubules. Activation of these receptors in the kidney increases the transcription and expression of the epithelial sodium channel (ENaC) and the basolateral Na+/K+-ATPase. This leads to significantly increased sodium reabsorption and subsequent water retention. The resulting intravascular volume expansion increases cardiac preload, which can precipitate or exacerbate congestive heart failure. For this reason, TZDs are strictly contraindicated in patients with symptomatic heart failure.

Step-by-Step Solution

1
Identify the medication class being considered and rejected.
The physician considered pioglitazone, a thiazolidinedione (TZD), but rejected it due to the patient's history of heart failure.
Recognizing the drug and its primary contraindication is required to understand which metabolic mechanism is being tested.
2
Recall the cellular target of thiazolidinediones.
TZDs bind to and activate the peroxisome proliferator-activated receptor-gamma (PPAR-\gamma), a nuclear transcription factor.
The question asks for the cellular mechanism leading to the specific side effect of fluid retention.
3
Determine how PPAR-\gamma activation leads to fluid retention.
PPAR-\gamma receptors in the renal collecting ducts stimulate the transcription of the epithelial sodium channel (ENaC), increasing renal sodium and water reabsorption.
Connecting the molecular target to the organ-specific physiological response explains the mechanism of the contraindication.

Key Concept

Mechanism of thiazolidinedione-induced fluid retention and heart failure exacerbation
Question 250Question →

An internist is evaluating a 48-year-old man who reports a 3-month history of persistent nasal crusting, recurrent epistaxis, and migratory arthralgias. Over the past two weeks, the patient has developed a cough that occasionally produces blood-tinged sputum. He has no prior medical history and takes no medications. Vital signs are within normal limits except for a blood pressure of 152/94 mm Hg. Physical examination reveals an ulcerated septal mucosa and a saddle-nose deformity. Laboratory testing shows a blood urea nitrogen of 38 mg/dL and a serum creatinine of 2.6 mg/dL. Urinalysis demonstrates 2+ protein, numerous dysmorphic red blood cells, and red blood cell casts. Which of the following immunopathologic mechanisms is most directly responsible for this patient's renal findings?

Show answer & explanation

Answer: Neutrophil activation and degranulation triggered by autoantibodies against granule proteins

Answer

Neutrophil activation and degranulation triggered by autoantibodies against granule proteins
This patient's clinical triad of upper respiratory tract destruction (nasal ulceration, saddle-nose deformity), lower respiratory tract involvement (hemoptysis), and glomerulonephritis (RBC casts, elevated creatinine) is the classic presentation of Granulomatosis with polyangiitis (GPA). GPA is an antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, most commonly involving anti-proteinase 3 (c-ANCA) autoantibodies. The pathogenesis involves circulating ANCAs binding to their target antigens on the surface of neutrophils that have been primed by inflammatory cytokines. This binding induces massive neutrophil activation, degranulation, and release of reactive oxygen species, which directly damage the adjacent vascular endothelium. In the kidney, this immune-mediated endothelial injury manifests as a pauci-immune necrotizing crescentic glomerulonephritis, producing the observed hematuria and red blood cell casts.

Step-by-Step Solution

1
Analyze the patient's clinical presentation.
The patient has upper respiratory tract involvement (nasal ulceration, saddle-nose deformity), lower respiratory tract involvement (hemoptysis), and rapidly progressive renal failure (elevated creatinine, RBC casts).
Identifying the specific pattern of affected organ systems is the first step in narrowing the differential diagnosis for systemic vasculitides.
2
Formulate a diagnosis based on the clinical triad.
The combination of upper respiratory, lower respiratory, and renal involvement is highly characteristic of Granulomatosis with polyangiitis (GPA).
GPA (formerly Wegener granulomatosis) classically presents with this triad and is strongly associated with c-ANCA (anti-proteinase 3 antibodies).
3
Identify the immunopathologic mechanism of the renal injury in this disease.
The renal pathology in GPA is a pauci-immune necrotizing crescentic glomerulonephritis. It is driven by circulating anti-neutrophil cytoplasmic antibodies (ANCAs) that bind and activate primed neutrophils, causing them to degranulate and damage the vascular endothelium.
Understanding the underlying molecular mechanism answers the specific question regarding the etiology of the renal findings.

Key Concept

Granulomatosis with polyangiitis (GPA) is a small-vessel vasculitis characterized by upper and lower respiratory tract necrotizing granulomas and a pauci-immune glomerulonephritis, mediated by ANCA-induced neutrophil activation.
Question 251Question →

A physician is managing a 45-year-old female patient who presents with resistant hypertension and spontaneous hypokalemia. Diagnostic testing reveals an elevated plasma aldosterone concentration to plasma renin activity ratio, and abdominal imaging confirms a unilateral adrenal adenoma. The patient's condition results in excessive sodium reabsorption in the distal nephron. Arrange the following cellular events in the correct chronological sequence to describe the physiological mechanism of action for the hormone overproduced in this condition.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct sequence begins with the hormone entering the cell via diffusion, followed by cytosolic receptor binding, nuclear translocation, gene transcription, and finally the insertion of sodium channels into the membrane.
Aldosterone is a lipophilic steroid hormone that exerts its effects primarily via a genomic mechanism. First, it diffuses across the basolateral membrane of the principal cells in the renal collecting duct. Second, it binds to the cytosolic mineralocorticoid receptor, inducing a conformational change and the shedding of associated chaperone proteins. Third, this active complex translocates into the nucleus. Fourth, it binds to specific DNA sequences to promote the transcription of aldosterone-induced proteins, particularly SGK1. Finally, SGK1 inhibits the ubiquitin ligase Nedd4-2, preventing the degradation of epithelial sodium channels (ENaC) and resulting in their increased insertion into the apical membrane.

Step-by-Step Solution

1
Identify the primary hormone involved based on the clinical presentation.
The patient has primary hyperaldosteronism (Conn syndrome), indicating that the hormone driving the pathology is aldosterone.
Identifying the hormone is required to determine its specific intracellular signaling pathway.
2
Determine the biochemical class of the hormone.
Aldosterone is a steroid hormone (mineralocorticoid).
Steroid hormones share a common genomic mechanism of action, differentiating them from peptide hormones that bind to extracellular cell-surface receptors.
3
Sequence the steroid hormone genomic signaling pathway.
Cellular diffusion -> Cytosolic receptor binding -> Nuclear translocation -> Gene transcription (AIPs/SGK1) -> Physiological effect (ENaC insertion).
This is the classic multi-step mechanism required for steroid hormones to exert their physiological effects on target tissues.

Key Concept

Steroid hormone mechanism of action (Aldosterone)
Question 252Question →

For each of the following clinical scenarios requiring targeted biologic therapy, select the precise immunopathologic mechanism of the most appropriate therapeutic agent.

Click a left item, then click its matching right item

Items

A 32-year-old woman with highly active relapsing-remitting multiple sclerosis requires escalation of therapy. Serological testing for the John Cunningham (JC) virus is negative.
A 45-year-old man with medically refractory chronic spontaneous urticaria continues to experience daily wheals and severe pruritus despite maximum tolerated doses of second-generation H1-antihistamines.
A 28-year-old woman is diagnosed with severe fistulizing Crohn disease and concurrent moderate-to-severe plaque psoriasis. She requires induction and maintenance therapy.
A 55-year-old man with newly diagnosed microscopic polyangiitis and rapidly progressive glomerulonephritis requires non-glucocorticoid induction therapy.

Matches

Show answer & explanation

Answer

The correct matches align each specific autoimmune or inflammatory condition with the precise molecular target of its corresponding first-line or escalation biologic agent: MS with alpha-4 integrin blockade, chronic urticaria with IgE binding, Crohn/psoriasis with IL-12/23 p40 inhibition, and microscopic polyangiitis with CD20 depletion.
Each clinical presentation requires a specific immunomodulator whose mechanism precisely targets the underlying pathophysiology of the disease. Natalizumab blocks leukocyte CNS entry in MS. Omalizumab neutralizes IgE in chronic urticaria. Ustekinumab halts the IL-12/23 inflammatory cascade in Crohn disease and psoriasis. Rituximab depletes the autoantibody-producing B cells in ANCA-associated vasculitis.

Step-by-Step Solution

1
Identify the indicated biologic agent for each specific clinical scenario.
Natalizumab is indicated for the MS patient. Omalizumab is indicated for the chronic urticaria patient. Ustekinumab is indicated for the patient with Crohn disease and psoriasis. Rituximab is indicated for the patient with microscopic polyangiitis.
Establishing the correct drug based on clinical presentation and guidelines is necessary before identifying its molecular mechanism.
2
Map each identified agent to its immunopharmacologic mechanism of action.
Natalizumab blocks alpha-4 integrin; Omalizumab binds circulating IgE; Ustekinumab targets the IL-12/23 p40 subunit; Rituximab depletes CD20+ B cells.
Demonstrates foundational knowledge of how targeted immunotherapies modulate specific immune cascades and pathways.

Key Concept

Understanding the precise immunologic targets of monoclonal antibodies is essential for selecting appropriate therapies and anticipating specific adverse effects or contraindications (e.g., PML risk with alpha-4 integrin blockade).
Question 253Question →

A 47-year-old woman comes to the clinic reporting worsening fatigue, increased thirst, and frequent urination over the past three months. She has a history of chronic cough and was told she had "enlarged lymph nodes" in her chest a year ago, but she did not follow up. Her temperature is 37.0°C (98.6°F), blood pressure is 128/82 mmHg, and pulse is 78/min. Physical examination reveals a few erythematous nodules on her anterior lower legs. Laboratory studies show:

Laboratory ParameterResultReference Range
Calcium, serum12.8 mg/dL8.4-10.2 mg/dL
Phosphorus, serum4.6 mg/dL2.5-4.5 mg/dL
Parathyroid hormone (PTH)9 pg/mL10-65 pg/mL
Creatinine, serum1.1 mg/dL0.6-1.1 mg/dL

Which of the following cellular mechanisms best explains this patient's current laboratory abnormalities?

Show answer & explanation

Answer: Unregulated conversion of 25-hydroxyvitamin D to 1,25-dihydroxyvitamin D by activated macrophages

Answer

Unregulated conversion of 25-hydroxyvitamin D to 1,25-dihydroxyvitamin D by activated macrophages
The correct answer is the unregulated conversion of 25-hydroxyvitamin D to 1,25-dihydroxyvitamin D by activated macrophages. This patient's presentation of hypercalcemia, suppressed parathyroid hormone (PTH), polyuria, and constitutional symptoms, along with a history of bilateral hilar lymphadenopathy and erythema nodosum, is highly suspicious for sarcoidosis. In sarcoidosis and other granulomatous diseases, disease-associated macrophages ectopically express the enzyme 1-alpha-hydroxylase. This enzyme converts 25-hydroxyvitamin D into the active form, 1,25-dihydroxyvitamin D (calcitriol), independent of normal physiologic feedback mechanisms. The excess calcitriol increases intestinal absorption of both calcium and phosphorus, leading to hypercalcemia and normal-to-elevated serum phosphorus. The resultant hypercalcemia suppresses endogenous PTH secretion from the parathyroid glands via negative feedback.

Step-by-Step Solution

1
Analyze the patient's clinical presentation.
The patient has fatigue, polyuria, a history of bilateral hilar lymphadenopathy, and erythema nodosum.
These findings are classic for sarcoidosis, a systemic granulomatous disease.
2
Interpret the laboratory findings.
The patient has severe hypercalcemia, slightly elevated phosphorus, and a definitively suppressed PTH level.
A suppressed PTH level indicates a PTH-independent mechanism of hypercalcemia, directing the differential diagnosis away from primary hyperparathyroidism.
3
Synthesize clinical and laboratory data to identify the cellular mechanism.
The hypercalcemia is driven by the underlying granulomatous disease process.
Granulomas contain activated macrophages that ectopically express 1-alpha-hydroxylase, which converts 25-hydroxyvitamin D to active 1,25-dihydroxyvitamin D, causing increased intestinal absorption of calcium and phosphorus.

Key Concept

The primary mechanism of hypercalcemia in sarcoidosis and other granulomatous diseases is the unregulated, ectopic production of 1,25-dihydroxyvitamin D (calcitriol) by 1-alpha-hydroxylase expressed in activated macrophages.
Question 254Question →

A 58-year-old man comes to the clinic reporting a two-month history of a persistent left-sided scrotal mass that feels like a 'bag of worms.' The mass does not decrease in size when he lies flat. He also reports intermittent episodes of pink-tinged urine over the past month. His past medical history is significant for a 30-pack-year smoking history, though he quit 5 years ago. His vital signs show a blood pressure of 150/95 mmHg, heart rate 82/min, and a BMI of 28 kg/m2. Physical examination confirms a left-sided varicocele that remains prominent in the supine position. Laboratory testing reveals a hemoglobin of 19.2 g/dL and a hematocrit of 58%. Which of the following best describes the molecular or pathophysiologic mechanism most directly responsible for the laboratory abnormality seen in this patient?

Show answer & explanation

Answer: Inappropriate stabilization of hypoxia-inducible factor leading to autonomous erythropoietin synthesis

Answer

Inappropriate stabilization of hypoxia-inducible factor leading to autonomous erythropoietin synthesis
The correct answer is inappropriate stabilization of hypoxia-inducible factor leading to autonomous erythropoietin synthesis. This patient's presentation of painless gross hematuria and a left-sided varicocele that fails to empty in the supine position is highly suspicious for a left-sided renal cell carcinoma (RCC). The left gonadal vein drains perpendicularly into the left renal vein. An RCC can extend into the renal vein, obstructing the gonadal vein and leading to a left-sided varicocele. Polycythemia (elevated hemoglobin and hematocrit) is a well-documented paraneoplastic syndrome of RCC. This occurs due to the ectopic production of erythropoietin (EPO). At the molecular level, clear cell RCCs are strongly associated with mutations in the von Hippel-Lindau (VHL) tumor suppressor gene. Loss of VHL function prevents the normal ubiquitination and degradation of hypoxia-inducible factor (HIF). The resulting inappropriate stabilization and accumulation of HIF leads to increased transcription of several target genes, including EPO, which causes secondary polycythemia.

Step-by-Step Solution

1
Analyze the physical exam findings to localize the primary lesion.
The patient has a left-sided varicocele that fails to empty when supine, alongside painless hematuria. This suggests an obstruction of the left renal vein, which the left gonadal vein drains into.
A varicocele that does not decompress raises high suspicion for a left-sided Renal Cell Carcinoma (RCC) invading the renal vein.
2
Evaluate the laboratory abnormalities in the context of the suspected lesion.
The elevated hemoglobin (19.2 g/dL) and hematocrit (58%) indicate polycythemia. In a patient with suspected RCC, this is a recognized paraneoplastic syndrome.
RCC can autonomously secrete hormones, most notably erythropoietin (EPO), causing secondary absolute polycythemia.
3
Determine the molecular mechanism underlying this specific paraneoplastic syndrome.
Ectopic EPO production in clear cell RCC is driven by mutations in the VHL tumor suppressor gene.
Loss of VHL prevents the degradation of hypoxia-inducible factor (HIF), leading to its stabilization and the subsequent autonomous transcription of EPO.

Key Concept

Renal cell carcinoma (RCC) can present with hematuria and a left-sided varicocele due to left renal vein invasion. It frequently causes paraneoplastic polycythemia due to VHL mutation-mediated stabilization of hypoxia-inducible factor (HIF), leading to autonomous erythropoietin production.
Question 255Question →

Various hereditary cancer syndromes are characterized by distinct clinical presentations and specific underlying molecular defects. Match each patient's clinical vignette with the fundamental genetic mechanism responsible for their disease pathogenesis.

Click a left item, then click its matching right item

Items

A 35-year-old female (BP 185/115 mmHg, HR 105 bpm) is evaluated for a rapidly enlarging thyroid mass. Physical exam notes oral mucosal neuromas. Labs demonstrate elevated serum calcitonin and 24-hour urine fractionated metanephrines.
An asymptomatic 42-year-old male with normal vital signs undergoes endoscopic screening due to family history. Gastroenterology reports the presence of approximately 300 adenomatous colonic polyps.
A 29-year-old female presents with progressive gait ataxia. Vital signs are within normal limits. Neuroimaging identifies a cerebellar hemangioblastoma, while concurrent abdominal ultrasound reveals bilateral renal cysts.
A 48-year-old female discovers a painless, fixed 3-cm breast mass. Vitals are unremarkable. Pathology confirms triple-negative invasive ductal carcinoma. Her pedigree includes a first-degree relative with high-grade serous ovarian cancer.

Matches

Show answer & explanation

Answer

MEN2B (vignette 1) is driven by RET receptor tyrosine kinase activation. FAP (vignette 2) is caused by APC mutation and failure to degrade β\beta-catenin. VHL disease (vignette 3) results from impaired HIF-1 α\alpha degradation. HBOC syndrome (vignette 4) is due to defective homologous recombination DNA repair.
This question requires a two-step reasoning process: first, diagnosing the hereditary cancer syndrome from the clinical vignette, and second, identifying the fundamental molecular defect responsible for that syndrome. The vignettes describe MEN2B (RET mutation), FAP (APC mutation), VHL disease (VHL mutation), and HBOC syndrome (BRCA mutation). Matching these clinical phenotypes to their respective receptor tyrosine kinase activation, Wnt/β\beta-catenin signaling dysregulation, impaired HIF-1 α\alpha degradation, and defective homologous recombination correctly maps the neoplastic processes.

Step-by-Step Solution

1
Analyze the first vignette to diagnose the syndrome and its genetic basis.
The triad of medullary thyroid cancer, pheochromocytoma, and mucosal neuromas diagnoses MEN2B, caused by RET receptor tyrosine kinase activation.
Recognizing the syndromic presentation is the first step to identifying the specific oncogenic driver.
2
Evaluate the second vignette's endoscopic findings.
Hundreds of colonic polyps indicate FAP, which results from APC gene mutation and failure to degrade β\beta-catenin.
FAP has a distinct molecular pathogenesis compared to other polyposis syndromes.
3
Identify the disease described in the third vignette.
Hemangioblastoma and renal cysts are classic for VHL disease, driven by impaired HIF-1 α\alpha degradation.
VHL mutations directly link defective angiogenesis regulation to tumor development.
4
Assess the fourth vignette's family history and pathology.
Triple-negative breast cancer and familial ovarian cancer suggest BRCA mutations, which impair double-strand DNA repair.
BRCA mutations exhibit a characteristic pattern of related malignancies due to genomic instability.

Key Concept

Molecular pathogenesis and genetic drivers of hereditary cancer syndromes
Question 256Question →

A 24-year-old woman is brought to the emergency department by her husband due to a 12-hour history of severe, progressively worsening abdominal pain, nausea, and multiple episodes of nonbilious vomiting. She has not had any fever, diarrhea, or melena. Her medical history is significant for several episodes of sudden-onset, nonpruritic lip and facial swelling over the past five years that typically resolved spontaneously after 2 to 3 days. Her father had a history of similar recurrent episodes of facial swelling. On physical examination, her temperature is 37.1°C (98.8°F), blood pressure is 110/70 mm Hg, pulse is 105/min, and respiratory rate is 16/min. The abdomen is diffusely tender with guarding but no rebound tenderness. There is no cutaneous rash, urticaria, or wheezing. A CT scan of the abdomen with intravenous contrast demonstrates segmental small bowel wall thickening and free pelvic fluid, without evidence of bowel obstruction. Laboratory evaluation shows a normal complete blood count, a normal basic metabolic panel, and a significantly decreased serum C4 level.

Administration of an agent with which of the following mechanisms of action is most appropriate for the acute management of this patient's current symptoms?

Show answer & explanation

Answer: Antagonism of bradykinin B2 receptors

Answer

Antagonism of bradykinin B2 receptors
The correct answer is antagonism of bradykinin B2 receptors. This patient is presenting with a gastrointestinal attack of hereditary angioedema (HAE). HAE is an autosomal dominant immunologic disorder caused by a quantitative or functional deficiency of C1 esterase inhibitor (C1-INH). C1-INH normally inhibits the classical complement pathway and the kallikrein-kinin system. Its absence leads to unchecked activation of kallikrein, resulting in excessive production of bradykinin, the primary mediator of vascular permeability in this disease. The chronically uninhibited cleavage of C4 by C1 makes a low serum C4 level a reliable diagnostic marker. Acute attacks can cause life-threatening laryngeal edema or severe abdominal pain due to bowel wall edema, mimicking a surgical abdomen. Acute management requires targeting the specific pathophysiologic pathway, utilizing agents such as a bradykinin B2 receptor antagonist (icatibant), a kallikrein inhibitor (ecallantide), or purified C1-INH concentrate.

Step-by-Step Solution

1
Analyze the clinical presentation and history.
The patient has recurrent episodes of nonpruritic swelling, severe abdominal pain (explained by bowel wall edema on CT), and a positive family history, strongly suggesting hereditary angioedema (HAE) rather than an allergic reaction.
Differentiating bradykinin-mediated angioedema (no urticaria, GI involvement) from histamine-mediated angioedema (urticaria, wheezing) is critical for acute management.
2
Evaluate the laboratory findings.
The significantly decreased serum C4 level confirms classical complement pathway consumption.
Low C4 is the primary screening test for C1 esterase inhibitor (C1-INH) deficiency, the underlying cause of HAE.
3
Identify the underlying immunopathologic mechanism.
C1-INH deficiency leads to uninhibited activation of the kallikrein-kinin system, resulting in massive overproduction of bradykinin, which causes profound vasodilation and increased vascular permeability.
Understanding the precise inflammatory mediator dictates the choice of pharmacotherapy.
4
Select the appropriate pharmacologic intervention.
Acute management of HAE requires blocking the effects of bradykinin (e.g., icatibant, a bradykinin B2 receptor antagonist), inhibiting kallikrein (ecallantide), or replacing C1-INH.
Standard allergic treatments (epinephrine, antihistamines, corticosteroids) are ineffective for bradykinin-mediated edema.

Key Concept

Pathophysiology and targeted pharmacotherapy of Hereditary Angioedema (HAE).
Question 257Question →

A 58-year-old man presents to the emergency department with profound weakness and an inability to stand. He has a 40-pack-year smoking history. Over the past three months, he has experienced a 12 kg12\text{ kg} (26 lb26\text{ lb}) weight loss and noticed darkening of his skin creases. Two weeks ago, his primary care physician started him on lisinopril and hydrochlorothiazide for new-onset hypertension. His blood pressure is 165/95 mm Hg165/95\text{ mm Hg}. Physical examination reveals temporal wasting, proximal muscle weakness, and hyperpigmentation of the palmar creases.

Laboratory studies show:
Sodium: 144 mEq/L144\text{ mEq/L}
Potassium: 2.1 mEq/L2.1\text{ mEq/L}
Chloride: 98 mEq/L98\text{ mEq/L}
Bicarbonate: 35 mEq/L35\text{ mEq/L}
Morning serum cortisol: 92 μg/dL92\text{ }\mu\text{g/dL} (Reference: 5−23 μg/dL5-23\text{ }\mu\text{g/dL})
Plasma ACTH: 480 pg/mL480\text{ pg/mL} (Reference: 10−60 pg/mL10-60\text{ pg/mL})

Based on the clinical presentation and laboratory findings, which of the following is the primary cellular mechanism responsible for this patient's profound hypokalemia?

Show answer & explanation

Answer: Saturation of the renal enzyme 11-\beta-hydroxysteroid dehydrogenase type 2

Answer

Saturation of the renal enzyme 11-\beta-hydroxysteroid dehydrogenase type 2
The correct mechanism is the saturation of the renal enzyme 11-beta-hydroxysteroid dehydrogenase type 2. This patient's presentation (weight loss, smoking history, hyperpigmentation, severe hypercortisolism, and markedly elevated ACTH) is classic for ectopic ACTH syndrome, most commonly due to small cell lung cancer. Cortisol binds to the mineralocorticoid receptor with the same affinity as aldosterone. Under normal conditions, the kidneys are protected from this mineralocorticoid effect by the enzyme 11-beta-hydroxysteroid dehydrogenase type 2, which converts active cortisol into inactive cortisone. However, in states of massive cortisol excess like ectopic ACTH syndrome, this enzyme is overwhelmed and saturated. The excess unmetabolized cortisol binds to mineralocorticoid receptors in the renal collecting duct, leading to unregulated sodium reabsorption and severe distal tubular potassium and hydrogen ion excretion.

Step-by-Step Solution

1
Analyze the clinical presentation and lab values.
The patient has severe hypokalemia, metabolic alkalosis, weight loss, hyperpigmentation, high cortisol, and very high ACTH.
Identifying the primary syndrome is necessary before determining the cellular mechanism of the electrolyte derangement.
2
Formulate a diagnosis based on the combined findings.
The combination of heavy smoking, weight loss, very high ACTH, and hypercortisolism strongly points to ectopic ACTH syndrome (likely secondary to small cell lung cancer).
Ectopic ACTH production explains the hyperpigmentation (co-secretion of MSH with ACTH) and massive hypercortisolism.
3
Connect the diagnosis to the specific electrolyte abnormality.
Identify how massive hypercortisolism causes mineralocorticoid excess effects (hypokalemia and metabolic alkalosis).
The question specifically asks for the cellular mechanism driving the profound hypokalemia.
4
Determine the biochemical mechanism of apparent mineralocorticoid excess in Cushing syndrome.
Cortisol binds with equal affinity to the mineralocorticoid receptor as aldosterone. Normally, 11-beta-HSD2 converts cortisol to inactive cortisone in the kidney. In ectopic ACTH, the massive amount of cortisol saturates this enzyme.
When 11-beta-HSD2 is saturated, excess active cortisol acts on the mineralocorticoid receptors in the distal tubule, causing sodium reabsorption and severe potassium wasting.

Key Concept

In conditions with massive hypercortisolism (such as ectopic ACTH syndrome), the renal enzyme 11-beta-hydroxysteroid dehydrogenase type 2 becomes saturated. This allows high levels of circulating cortisol to cross-react with and activate the mineralocorticoid receptor, resulting in severe hypokalemia, metabolic alkalosis, and hypertension.
Question 258Question →

A 1919-year-old male of West African descent is admitted to the inpatient oncology unit for the initiation of induction chemotherapy after being diagnosed with bulky Burkitt lymphoma. His baseline renal function and electrolyte panels are within normal limits. Thirty-six hours after starting a cytotoxic regimen containing cyclophosphamide, doxorubicin, vincristine, and methotrexate, he reports severe nausea, muscle twitching, and significantly reduced urine output.

An electrocardiogram shows peaked T waves. Laboratory evaluation reveals the following:

TestResult
Potassium6.76.7 mEq/L
Calcium6.26.2 mg/dL
Phosphorus8.88.8 mg/dL
Uric acid16.416.4 mg/dL
Creatinine3.13.1 mg/dL

The attending physician plans to prescribe a recombinant urate oxidase enzyme to rapidly lower the patient's uric acid levels. Which of the following patient factors represents an absolute contraindication to this specific pharmacologic intervention?

Show answer & explanation

Answer: Glucose-6-phosphate dehydrogenase deficiency

Answer

Glucose-6-phosphate dehydrogenase (G6PD) deficiency is an absolute contraindication to rasburicase therapy.
The correct answer is Glucose-6-phosphate dehydrogenase (G6PD) deficiency. The patient has Tumor Lysis Syndrome (TLS) and requires rapid lowering of uric acid levels. The physician plans to use rasburicase, a recombinant urate oxidase. This enzyme facilitates the conversion of uric acid into allantoin, an inactive and highly soluble metabolite. However, this biochemical reaction also produces hydrogen peroxide (H2O2H_2O_2), a potent oxidizing agent. Red blood cells rely entirely on the G6PD enzyme to generate NADPH, which is necessary to maintain a supply of reduced glutathione to neutralize oxidative stressors like H2O2H_2O_2. In a patient with G6PD deficiency, administering rasburicase leads to overwhelming oxidative stress, resulting in severe hemolytic anemia and methemoglobinemia. Therefore, G6PD deficiency is an absolute contraindication to rasburicase, and testing is recommended in high-risk populations prior to administration.

Step-by-Step Solution

1
Identify the patient's primary clinical syndrome.
The patient has developed Tumor Lysis Syndrome (TLS), characterized by hyperkalemia, hyperphosphatemia, hypocalcemia, hyperuricemia, and acute kidney injury following chemotherapy for a rapidly proliferating tumor.
Recognizing the syndrome contextualizes the need for aggressive metabolic management.
2
Determine the mechanism of action of the planned medication.
The planned drug is rasburicase, a recombinant urate oxidase that catalyzes the oxidation of uric acid to the highly soluble compound allantoin.
Understanding the pharmacodynamics is necessary to identify potential adverse effects and contraindications.
3
Identify the toxic byproducts of the enzymatic reaction.
The conversion of uric acid to allantoin by urate oxidase produces hydrogen peroxide (H2O2H_2O_2) as a metabolic byproduct.
The byproduct is responsible for the specific absolute contraindication associated with this drug.
4
Correlate the toxic byproduct with patient-specific risk factors.
Patients with Glucose-6-phosphate dehydrogenase (G6PD) deficiency cannot produce adequate NADPH to reduce glutathione. They are unable to neutralize the H2O2H_2O_2 oxidative stress, leading to life-threatening hemolysis and methemoglobinemia.
This establishes why G6PD deficiency must be ruled out (often highly relevant in patients of West African descent) before administering rasburicase.

Key Concept

Rasburicase (recombinant urate oxidase) produces hydrogen peroxide (H2O2H_2O_2) during the breakdown of uric acid, making it absolutely contraindicated in patients with G6PD deficiency due to the risk of severe hemolysis and methemoglobinemia.
Question 259Question →

Emergency medical services transport a 22-year-old woman to the hospital after her roommate found her lethargic and confused. Over the past 12 hours, she has experienced a high fever, repeated vomiting, and profuse diarrhea. Her medical history is notable for severe epistaxis, for which an anterior nasal packing was placed at an urgent care clinic three days ago. Current vital signs are temperature 39.5°C (103.1°F), blood pressure 82/45 mmHg, pulse 135/min, and respiratory rate 24/min. Physical examination reveals a diffuse, erythematous, macular rash that resembles a severe sunburn covering her trunk and extremities. Her sclerae are markedly injected, and the oral mucosa is hyperemic. The nasal packing remains in place and appears saturated. Which of the following best describes the molecular mechanism responsible for this patient's rapid hemodynamic collapse?

Show answer & explanation

Answer: Simultaneous binding of an exotoxin to major histocompatibility complex class II molecules and T-cell receptors

Answer

The correct underlying mechanism is the simultaneous binding of an exotoxin to major histocompatibility complex class II molecules and T-cell receptors, characteristic of a superantigen causing Toxic Shock Syndrome.
The correct answer describes the mechanism of a superantigen, which is responsible for Toxic Shock Syndrome (TSS). The patient's clinical presentation of high fever, profound hypotension, vomiting, diarrhea, mucosal hyperemia, and a diffuse sunburn-like macular erythroderma following the placement of a nasal packing is highly characteristic of TSS. Staphylococcus aureus can colonize retained foreign bodies (such as tampons or nasal packing) and produce Toxic Shock Syndrome Toxin-1 (TSST-1). TSST-1 acts as a superantigen by binding directly to the major histocompatibility complex (MHC) class II molecule on antigen-presenting cells and the variable region of the beta chain (V-beta) on T-cell receptors. This cross-linkage occurs outside the conventional peptide-binding groove and indiscriminately activates up to 20% of the body's T-cells, leading to a massive, uncontrolled release of inflammatory cytokines (such as IL-1, IL-2, TNF-alpha, and IFN-gamma) known as a cytokine storm. This massive cytokine release is the direct cause of the patient's rapid hemodynamic collapse and multiorgan dysfunction.

Step-by-Step Solution

1
Analyze the clinical presentation to identify the primary syndrome.
The patient presents with rapid-onset shock, high fever, gastrointestinal symptoms, mucosal hyperemia, and a diffuse sunburn-like rash, in the setting of a retained foreign body (nasal packing).
Identifying the classic symptom cluster is essential for differentiating the etiology of the shock state.
2
Formulate the most likely diagnosis based on the clinical context.
The constellation of symptoms strongly indicates Toxic Shock Syndrome (TSS), most likely caused by Staphylococcus aureus proliferating in the retained nasal packing.
Accurate clinical diagnosis directs the physician to the correct underlying pathophysiology.
3
Determine the specific immunopathologic mechanism of the causative agent.
S. aureus produces Toxic Shock Syndrome Toxin-1 (TSST-1), a superantigen that nonspecifically links MHC-II and T-cell receptors outside the normal antigen-binding groove, causing a massive cytokine storm.
Understanding the mechanism of superantigens is critical for distinguishing TSS from other forms of distributive shock and infectious rashes.

Key Concept

Toxic Shock Syndrome Toxin-1 (TSST-1) is a superantigen that nonspecifically bridges MHC-II and T-cell receptors, leading to massive T-cell activation and life-threatening cytokine release.
Question 260Question →

An ambulance brings a 68-year-old male patient to the acute care unit due to altered mental status and hyperventilation that began earlier today. His wife reports that he had a severe gastrointestinal illness over the last three days with profound watery diarrhea, leading to significantly decreased oral fluid intake. His past medical history is significant for hypertension, stable angina, and type 2 diabetes mellitus. He has continued to take his prescribed daily medications despite his recent illness.

Physical examination reveals a lethargic, difficult-to-arouse patient with deep, rapid respirations. Vital signs include a blood pressure of 88/54 mm Hg, heart rate of 115/min, and respiratory rate of 28/min. The abdomen is diffusely tender but soft.

Initial laboratory evaluation shows:
- Sodium: 138 mEq/L
- Potassium: 5.2 mEq/L
- Chloride: 98 mEq/L
- Bicarbonate: 10 mEq/L
- Blood urea nitrogen: 54 mg/dL
- Creatinine: 3.2 mg/dL (baseline was 1.4 mg/dL one month ago)
- Glucose: 145 mg/dL
- Lactate: 9.5 mmol/L (Normal: 0.5 - 2.2 mmol/L)

An arterial blood gas drawn on room air demonstrates a pH of 7.22 and a pCO2 of 24 mm Hg.

The drug most likely responsible for this acute presentation lowers serum glucose primarily through which of the following cellular mechanisms?

Show answer & explanation

Answer: Inhibition of mitochondrial glycerophosphate dehydrogenase and complex I

Answer

Inhibition of mitochondrial glycerophosphate dehydrogenase and complex I
The correct answer identifies the cellular mechanism of metformin. This patient is presenting with a classic case of metformin-induced lactic acidosis. He developed an acute kidney injury secondary to volume depletion from severe gastroenteritis. Because metformin is cleared unchanged by the kidneys, acute renal failure leads to drug accumulation. Toxic levels of metformin interfere with mitochondrial respiration by inhibiting mitochondrial glycerophosphate dehydrogenase (mGPD) and complex I of the electron transport chain. This inhibition disrupts the conversion of lactate to pyruvate in the liver, leading to a profound accumulation of lactate and a severe high anion gap metabolic acidosis. Metformin's therapeutic effect of reducing hepatic gluconeogenesis also stems from this pathway, as the resulting increased intracellular AMP levels activate AMP-activated protein kinase (AMPK).

Step-by-Step Solution

1
Analyze the acid-base and electrolyte values to determine the primary metabolic derangement.
The patient has a severe high anion gap metabolic acidosis (pH 7.22, bicarbonate 10 mEq/L, anion gap = 138 - (98 + 10) = 30 mEq/L) with appropriate respiratory compensation.
Categorizing the metabolic state is essential to narrowing the differential diagnosis for the patient's altered mental status and hyperventilation.
2
Identify the specific cause of the high anion gap metabolic acidosis using the provided laboratory data.
The remarkably elevated serum lactate level (9.5 mmol/L) definitively identifies lactic acidosis as the cause of the high anion gap.
Different etiologies of high anion gap metabolic acidosis (e.g., ketoacidosis, uremia, toxic alcohols, lactic acidosis) require distinct management strategies.
3
Connect the etiology of the lactic acidosis to the patient's clinical history and medication use.
The patient has an acute kidney injury (creatinine 3.2 mg/dL) from severe volume depletion. In a patient taking medications for type 2 diabetes, this acute renal failure triggers the accumulation of renally-cleared metformin, leading to metformin-induced lactic acidosis.
Establishing the pharmacological trigger is necessary to answer the prompt regarding the offending drug.
4
Identify the cellular mechanism of action for the offending drug (metformin).
Metformin primarily lowers blood glucose by inhibiting mitochondrial glycerophosphate dehydrogenase (mGPD) and complex I of the electron transport chain.
The stem explicitly asks for the underlying molecular pathway of the responsible medication.

Key Concept

Metformin reduces hepatic gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase and complex I; it can cause severe, life-threatening lactic acidosis when it accumulates in the setting of acute kidney injury.
PreviousPage 13 / 22Next
Foundational Science and Mechanisms of Disease Practice Questions — USMLE Step 3 — Page 13 | Examkin